Article

Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3-ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial

2020-11-04

Abstract excerpt

Background: Single-agent gilteritinib and quizartinib (quiz) met their primary endpoints of improved overall survival (OS) in relapsed/refractory (R/R) FLT3-mut AML in phase III studies, but CRc durations were short (4-11 months). Quiz demonstrated potent synergy with venetoclax (VEN) (a BCL-2 inhibitor) in AML cell lines and PDX models (Mali et al. Haematologica 2020). Methods: Newly diagnosed or R/R AML with ECO...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e2b774e9-9ad9-5980-9f73-b165de8eb648
DOI: 10.1182/blood-2020-142687

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3-ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II TrialDOI 10.1182/blood-2020-142687Read

Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML.Semantic proximity Read

Quizartinib: a new hope in acute myeloid leukemia, an applied comprehensive review.Semantic proximity Read

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemiaSemantic proximity Read

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.Semantic proximity Read

Quizartinib for the treatment of acute myeloid leukemia.Semantic proximity Read

Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITDSemantic proximity Read

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia modelsSemantic proximity Read

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.Semantic proximity Read

Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3 -ITD Mutant/ TP53 Wild-type Acute Myeloid LeukemiasSemantic proximity Read

The role of quizartinib in the treatment of acute myeloid leukemia.Semantic proximity Read

Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia.Semantic proximity Read

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 MutationsSemantic proximity Read